ConductScience.org, home

Paper20549698

p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.

Fernandez-Cuesta L and 3 others. Int J Cancer, 2011. Cited by 30 papers, by iCite.

Cite this record

ConductScience Library. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Papers, record 20549698. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20549698

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
PubMed
Journal
Int J Cancer
PubMed
Year
2011
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
30
iCite
Relative citation ratio, by iCite
0.71
iCite
Revised in PubMed
2026-01-28
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fernandez-Cuesta LLynnette
2Anaganti SSuresh
3Hainaut PPierre
4Olivier MMagali

Source PubMed

Download CSV of authors

Topics24

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, HormonalMajor topic
Breast NeoplasmsMajor topic
EstradiolMajor topic
TamoxifenMajor topic
Tumor Suppressor Protein p53Major topic
Apoptosis
Blotting, Western
Cell Cycle
Cell Line, Tumor
Cell Proliferation
Drug Resistance, Neoplasm
ErbB Receptors
Estrogen Antagonists
Estrogen Receptor alpha
Estrogens
Female
Flow Cytometry
Fulvestrant
Humans
Immunoenzyme Techniques
RNA, Messenger
RNA, Small Interfering
Erb-b2 Receptor Tyrosine Kinases
Reverse Transcriptase Polymerase Chain Reaction

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
07-0606Worldwide Cancer ResearchUnited KingdomPubMed

Source PubMed

Download CSV of grants

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.

PMIDTitleJournalYearIn PapersSource
41939469Tamoxifen differentially modulates endometrial hyperplasia via wild-type and mutant p53 regulation of the ALKBH5-REG1A axis.Front Oncol2026https://conductscience.org/library/papers/41939469PubMed
41160600p53 regulates the expression of histone modifiers to restrict stemness and maintain differentiated luminal identity in breast cancer.Proc Natl Acad Sci U S A2025https://conductscience.org/library/papers/41160600PubMed
41026455Genetic and epigenetic contribution to tamoxifen resistance in breast cancer, concepts to drive therapeutic strategies.Discov Oncol2025https://conductscience.org/library/papers/41026455PubMed
40072091Sex Disparities in P53 Regulation and Functions: Novel Insights for Personalized Cancer Therapies.Cells2025https://conductscience.org/library/papers/40072091PubMed
39191497P53 Status Influences the Anti-proliferative Effect Induced by IFITM1 Inhibition in Estrogen Receptor-positive Breast Cancer Cells.Cancer Genomics Proteomics2024https://conductscience.org/library/papers/39191497PubMed
37627092BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer.Cancers (Basel)2023https://conductscience.org/library/papers/37627092PubMed
34441794Invasion and Metastasis as a Central Hallmark of Breast Cancer.J Clin Med2021https://conductscience.org/library/papers/34441794PubMed
34307167Role of Sex in the Therapeutic Targeting of p53 Circuitry.Front Oncol2021https://conductscience.org/library/papers/34307167PubMed
32695778Tamoxifen Rechallenge Decreases Metastatic Potential but Increases Cell Viability and Clonogenicity in a Tamoxifen-Mediated Cytotoxicity-Resistant Subline of Human Breast MCF7 Cancer Cells.Front Cell Dev Biol2020https://conductscience.org/library/papers/32695778PubMed
32061310TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.Trends Cancer2020https://conductscience.org/library/papers/32061310PubMed
29991800Tamoxifen overrides autophagy inhibition in Beclin-1-deficient glioma cells and their resistance to adenovirus-mediated oncolysis via upregulation of PUMA and BAX.Oncogene2018https://conductscience.org/library/papers/29991800PubMed
27503997Somatic TP53 Mutations in the Era of Genome Sequencing.Cold Spring Harb Perspect Med2016https://conductscience.org/library/papers/27503997PubMed
23865427The p53-estrogen receptor loop in cancer.Curr Mol Med2013https://conductscience.org/library/papers/23865427PubMed
23372829Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential.PLoS One2013https://conductscience.org/library/papers/23372829PubMed
23079576Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway.Br J Cancer2012https://conductscience.org/library/papers/23079576PubMed
21761402Early onset HER2-positive breast cancer is associated with germline TP53 mutations.Cancer2012https://conductscience.org/library/papers/21761402PubMed
21760703TP53 status and response to treatment in breast cancers.J Biomed Biotechnol2011https://conductscience.org/library/papers/21760703PubMed

Download CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20549698

GET https://conductscience.org/api/papers/v1/20549698/authors